Midi Health Review: What the Platform Does Well and Where It Falls Short for Women

What Midi Health Actually Is (and What It Is Not)

Midi Health is a women's telehealth company founded in 2021 with a specific mission: bring menopause-literate clinicians to women who can't find them locally. That mission addresses a documented crisis. A 2022 ACOG survey found that fewer than 20% of OB-GYN residency programs include formal menopause training, meaning most women cannot find a menopause-fluent clinician even when they try.

Midi's model pairs patients with nurse practitioners, physician assistants, and physicians who have received additional training in hormonal health. Visits are conducted via video. The platform accepts insurance from major commercial carriers, which genuinely differentiates it from many cash-only menopause telehealth competitors.

What Midi is not: a full-spectrum women's health practice. It does not offer obstetric care, fertility treatment, or gynecological procedures. The platform exists specifically in the perimenopause-to-postmenopause corridor, and that focus is both its strength and its most significant structural limitation.

Who Is Typically Seeking Midi?

Women who find Midi usually fall into one of three groups. First, women in their 40s experiencing perimenopausal symptoms (irregular cycles, sleep disruption, mood changes, vasomotor symptoms) whose primary care providers have dismissed their concerns or delayed hormone therapy unnecessarily. Second, postmenopausal women already on hormone therapy who want a provider who understands nuance rather than defaulting to fear. Third, women who have read updated guidelines and want a clinician who has read the same ones.

The Access Gap Midi Was Built to Solve

The Menopause Society (formerly NAMS) estimated in 2022 that there are fewer than 1,000 NAMS-certified menopause practitioners in the United States, serving a population of roughly 6,000 women per certified practitioner. That arithmetic is brutal. Midi's telehealth model attempts to address that gap at scale, and for basic hormone therapy initiation, it largely succeeds.

What Midi Health Does Well

Midi deserves credit where it earns it. Dismissing the platform entirely would leave real women with fewer options.

Hormone Therapy Prescribing

Midi prescribes FDA-approved hormone therapy including transdermal estradiol patches and gels, oral micronized progesterone (Prometrium), vaginal estrogen (including low-dose vaginal estradiol rings and tablets), and testosterone (off-label, compounded or commercial). This formulary aligns reasonably well with current Menopause Society guidance, which notes that transdermal estradiol carries lower venous thromboembolism risk than oral estrogen and is preferred in women with cardiovascular risk factors.

The platform also prescribes non-hormonal options for women who cannot or prefer not to take estrogen. Fezolinetant (Veozah), the neurokinin 3 receptor antagonist FDA-approved in May 2023 for moderate-to-severe vasomotor symptoms, is an example of a newer agent that evidence-based menopause platforms should offer.

Insurance Integration

Cash-pay-only telehealth is not equitable care. Midi's insurance integration, while imperfect in practice (prior authorizations for HRT remain a consistent friction point for users), is a structural advantage. Women on Medicaid or lower-cost commercial plans can sometimes access Midi in ways they cannot access boutique menopause practices.

Clinician Training Model

Midi trains its clinicians specifically in hormonal health, which is more than most primary care settings offer. The platform has published a clinical approach that references Menopause Society guidelines. Internal training standards are not publicly auditable, and the depth of that training likely varies by individual clinician.

Where Midi Falls Short: The Clinical Gaps

This is where an honest review has to be specific. The gaps are not trivial for women with complex needs.

Gap 1: The Perimenopause Diagnostic Problem

Perimenopause diagnosis is clinical, not purely laboratory-based. The Menopause Society is explicit: FSH and estradiol levels are not reliable diagnostic tools during perimenopause because they fluctuate dramatically from cycle to cycle and even within a single cycle. A woman can have a normal FSH on the day of her telehealth visit and be definitively perimenopausal by any clinical measure.

Telehealth platforms in general, and Midi in particular, can over-rely on lab values because they lack the physical exam component that supports a more nuanced clinical picture. A woman's reported symptom pattern, menstrual history, and cycle changes over time are the diagnostic backbone for perimenopause. If a clinician dismisses symptoms because "your labs look fine," that is a failure of clinical reasoning, not a lab result problem.

A WomanRx clinical framework for evaluating any menopause telehealth platform: Ask whether the platform can diagnose perimenopause in a woman aged 45 with irregular cycles and classic symptoms even when FSH is within the normal range. The correct answer, per Menopause Society guidance, is yes. If a platform's clinicians hesitate, that is a red flag about training depth.

Gap 2: PCOS Across the Life Span

PCOS affects an estimated 6 to 12% of women of reproductive age in the United States, making it the most common endocrine disorder in women. PCOS does not resolve at menopause. The androgen excess, insulin resistance, and metabolic risk that characterize PCOS during reproductive years persist into perimenopause and postmenopause, where they interact with the already-elevated cardiometabolic risk of estrogen loss.

Midi's clinical scope does not appear to include formal PCOS diagnosis or management. A perimenopausal woman with undiagnosed or poorly managed PCOS presents a more complex hormonal picture than a woman with straightforward estrogen deficiency. Progesterone choice, testosterone dosing, and metabolic monitoring all need adjustment in the PCOS context. A platform that addresses menopause without addressing PCOS is missing a condition that directly shapes how menopause hormone therapy should be tailored.

Gap 3: Thyroid Disease and Its Interaction with Menopause

Hypothyroidism and hyperthyroidism are far more common in women than in men. Women are 5 to 8 times more likely than men to develop thyroid disease, and thyroid dysfunction peaks in the perimenopausal and postmenopausal years. Hypothyroid symptoms overlap substantially with perimenopausal symptoms: fatigue, brain fog, weight changes, sleep disruption, mood changes. A platform that evaluates perimenopausal symptoms without ordering or reviewing thyroid function testing may miss a primary thyroid disorder or fail to recognize that a woman's HRT response is blunted because her TSH is poorly controlled.

Midi does review basic labs and may order thyroid panels, but active thyroid disease management is outside its stated scope. A woman with Hashimoto's thyroiditis entering perimenopause needs a provider who can adjust levothyroxine dosing alongside HRT initiation, because estrogen therapy increases thyroxine-binding globulin and may raise levothyroxine requirements. That cross-specialty coordination is difficult in a pure-telehealth menopause silo.

Gap 4: Bone Health and Osteoporosis Risk

Estrogen is the primary protective hormone for bone density in women. Bone loss accelerates sharply in the two to three years around the final menstrual period, with some women losing 2 to 3% of bone mineral density per year during early postmenopause. The US Preventive Services Task Force recommends screening osteoporosis with DXA in all women aged 65 and older and in younger postmenopausal women with equivalent fracture risk.

Prescribing HRT without formally assessing bone health, or without a pathway to DXA ordering and interpretation, leaves a meaningful gap. Midi's clinicians may discuss bone health and encourage patients to get DXA scans through primary care. That is a workaround, not a clinical service. Women with osteopenia or established osteoporosis may need bisphosphonates, denosumab, or other treatments alongside HRT, and that coordination requires a provider relationship that can span across these decisions.

Gap 5: Mental Health in the Hormonal Transition

Perimenopause is associated with a significantly elevated risk of new-onset or recurrent depression. The SWAN (Study of Women's Health Across the Nation) found that women in perimenopause were approximately 2.5 times more likely to report depressive symptoms than premenopausal women, independent of prior depression history. This is a neurobiological phenomenon driven by estrogen's effects on serotonin, dopamine, and GABA pathways, not simply a psychological response to aging.

Effective management of perimenopausal depression may involve hormone therapy, antidepressants, or both. Midi can prescribe hormone therapy. Managing the psychiatric dimension, diagnosing new major depressive disorder, adjusting SSRIs or SNRIs in the context of HRT, recognizing perimenopausal anxiety as distinct from generalized anxiety disorder, requires either in-house mental health services or warm-handoff coordination that is not part of Midi's described model.

Gap 6: No Fertility or Preconception Services

Women in their late 30s and early 40s increasingly face a dual reality: they are experiencing perimenopausal symptoms while still trying to conceive, or while still using contraception because they have not confirmed natural infertility. Spontaneous conception remains possible until the final menstrual period, and ovulatory cycles can occur sporadically even through perimenopause.

Midi does not offer fertility counseling, ovulation induction, or contraception management. A woman aged 43 asking "do I need birth control or do I need HRT or do I need both?" is asking a question Midi is structurally not set up to answer completely. Some forms of HRT are not adequate contraception. ACOG recommends that women use reliable contraception until 12 consecutive months of amenorrhea have occurred (for women over 50) or 24 months (for women under 50). A platform that prescribes HRT without addressing contraception needs for perimenopausal women who are not yet definitively postmenopausal is leaving a clinical gap with real consequences.

Pregnancy, Lactation, and Contraception: A Required Clinical Note

Because Midi prescribes hormonal medications, pregnancy and lactation safety must be addressed directly. This is not a minor administrative note. It is a clinical requirement.

Estrogen-based hormone therapy is contraindicated in pregnancy. Systemic estrogen should not be initiated or continued in any woman with a positive pregnancy test or with confirmed intrauterine pregnancy. Midi's clinical intake presumably screens for pregnancy status, but perimenopausal women who do not believe they can conceive may not disclose or may not themselves be aware of an early pregnancy. Any clinician prescribing systemic estrogen to a woman who has not completed her menopause transition should confirm pregnancy status.

Progesterone and pregnancy. Oral micronized progesterone (Prometrium) is used therapeutically in early pregnancy to support luteal phase in some fertility contexts, but when prescribed as HRT for endometrial protection, it is typically combined with systemic estrogen, a combination that is not used in pregnancy. The prescribing clinician must distinguish between these clinical contexts.

Lactation. Postpartum women are not Midi's target population, but a woman aged 40 or older who is postpartum and breastfeeding while also experiencing hormonal symptoms may encounter Midi's platform. Systemic estrogen during breastfeeding may suppress milk supply. Vaginal estrogen at low doses has minimal systemic absorption and limited evidence of harm to breastfed infants, but this decision requires careful individual assessment.

Contraception for perimenopausal women on HRT. HRT (standard-dose transdermal estradiol plus progesterone) is not a contraceptive. Perimenopausal women who have not confirmed natural infertility need a separate contraception plan. Low-dose combined hormonal contraception, progestin-only pills, an IUD, or other barrier methods may all be appropriate depending on cardiovascular risk profile, smoking history, and preference. This is a conversation Midi should be having with every perimenopausal patient who has not reached confirmed postmenopause.

Is Midi Health Legit? Evaluating Credibility

Yes, Midi Health is a legitimate clinical service. It is not a supplement company selling hormone "support" products, and it is not an unregulated gray-market pharmacy. Clinicians are licensed, prescriptions are issued through regulated pharmacies, and the clinical approach references published guidelines.

Legitimate does not mean perfect or complete. A clinic can be fully legitimate and still have scope limitations that matter for specific patients.

The Menopause Society's 2022 position statement on hormone therapy, available at menopause.org, provides the clearest benchmark for evaluating any menopause prescriber. The statement affirms that for healthy women under 60 or within 10 years of menopause onset, the benefits of HRT for symptom management generally outweigh the risks. Platforms that align with this guidance, as Midi appears to, are practicing evidence-based care.

The legitimacy question is better reframed: Is Midi the right platform for your specific clinical situation? For a 51-year-old woman with straightforward vasomotor symptoms, a normal metabolic panel, and no complex comorbidities, Midi may be entirely appropriate. For a 44-year-old with PCOS, Hashimoto's thyroiditis, perimenopausal depression, and questions about contraception, Midi's scope may not be sufficient.

Midi Health vs. Alternatives: A Comparative View

Several telehealth platforms now occupy the menopause-care space. The comparison below addresses clinical scope rather than pricing, because clinical scope is what determines appropriateness for a given woman's needs.

Alloy Health focuses on postmenopause and uses a questionnaire-driven prescribing model with physician review. Its scope is similarly limited to hormonal symptom management, with less capacity for complex comorbidity management.

Gennev (now part of Unified Women's Healthcare) has offered menopause coaching alongside clinical care and in some markets provides access to in-person gynecologists, which extends its scope for physical exam needs.

Evernow operates a similar telehealth prescribing model with physician oversight. Like Midi, its primary value is in HRT access and education.

Winona prescribes compounded bioidentical hormones, which carries a different risk profile. The FDA does not regulate compounded preparations for efficacy and safety in the same way it regulates approved products. The Menopause Society notes that FDA-approved hormone products are generally preferred over compounded products because compounding quality varies significantly between pharmacies.

None of these platforms replaces a comprehensive women's health practice that can coordinate gynecology, endocrinology, mental health, and primary care. They are access solutions for specific clinical tasks, most effectively for uncomplicated HRT initiation and ongoing management.

Who Midi Health Is Right For (and Who It Is Not)

A good fit:

• Women aged 45 and older with classic perimenopausal or postmenopausal vasomotor symptoms who have been unable to access a knowledgeable local clinician.
• Postmenopausal women who are already stable on HRT and need ongoing prescription management.
• Women whose primary barrier to care is geographic or scheduling.
• Women who have done their own research on hormone therapy and want a provider who will engage at that level.

Not a strong fit:

• Women with active PCOS requiring management across reproductive and menopausal transitions.
• Women with poorly controlled thyroid disease who need integrated endocrine management.
• Women in their late 30s or 40s who still need contraception or fertility guidance alongside hormonal symptom management.
• Women with significant perimenopausal depression or anxiety requiring psychiatric co-management.
• Women with established osteoporosis or complex fracture risk who need integrated bone health treatment.
• Postpartum women or women who are breastfeeding.
• Women with a personal or first-degree family history of hormone-sensitive cancers requiring individualized risk discussion beyond standard HRT candidacy screening.

What to Ask a Midi Clinician Before You Commit

A few specific questions will tell you quickly whether any telehealth menopause platform, including Midi, has the clinical depth your situation requires.

Ask: "If my labs look normal but my symptoms are consistent with perimenopause, will you treat based on clinical picture?" The correct answer is yes.

Ask: "Do you manage testosterone off-label for low libido, and what monitoring do you use?" The clinician should describe baseline total testosterone, hematocrit, and lipid monitoring per established off-label practice.

Ask: "If I need a DXA scan or a referral to an endocrinologist, how does your platform support that?" A good platform has a clear referral pathway.

Ask: "I am perimenopausal but not confirmed postmenopausal. Will we discuss contraception as well as HRT?" If the answer is "we only manage hormones," that is an honest but incomplete answer to your clinical needs.